Dr. César López-Camacho

César López-Camacho holds a PhD in Molecular Biology from the University of Manchester, United Kingdom, and has held four postdoctoral positions in molecular biology, fidelity of gene expression, and vaccinology at UMASS Medical School-USA, University of Vermont College of Medicine-USA and the Jenner Institute at University of Oxford, respectively. He is currently a Senior Postdoctoral Researcher working with Prof. Gavin Screaton at the Wellcome Centre for Human Genetics, here at Oxford. 

Since the COVID-19 outbreak, his current scientific activity encompasses the design and protein production of SARS-CoV-2 antigens to be utilised as diagnostic tools and for coronavirus research applications and the exploration of the immune responses in COVID-19 convalescent individuals.

He is part of the COVID-19 Outbreak Expert Database for the UK parliament; part of the National COVID Testing Scientific Advisory Panel and joined the College of Experts to Support the Global Effort on COVID-19 (GECO), as grant applications reviewer. 

In the pre-COVID era, his main research aims are the immunopathogenesis of Dengue virus and vaccine development of novel antigen candidates, to induce specific anti-flavivirus antibody responses against functional and conformational epitopes. 

Doctor López-Camacho joined the Jenner Institute in 2014 as a postdoctoral researcher in Reyes-Sandoval’s group and worked on vaccine development for several arboviruses (Zika, Dengue, Chikungunya and Mayaro viruses). During this time he extensively published scientific work, both as first author and as co-author, in relation to arboviral, parasitic (malaria and chagas disease) and Papillomavirus vaccine developments.

In terms of intellectual property activities, he is an inventor and collaborator in vaccine-related Patents. 

Dengue Vaccines

Zika virus vaccine and combination vaccine